Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Aggregation-induced emission (AIE), life and health
Light has profoundly impacted modern medicine and healthcare, with numerous
luminescent agents and imaging techniques currently being used to assess health and treat …
luminescent agents and imaging techniques currently being used to assess health and treat …
High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging
Resolving the spatial distribution of RNA and protein in tissues at subcellular resolution is a
challenge in the field of spatial biology. We describe spatial molecular imaging, a system …
challenge in the field of spatial biology. We describe spatial molecular imaging, a system …
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
First-line immunotherapy for non–small-cell lung cancer
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …
been characterized by critical progress that has contributed to substantially improved …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …
recommended management of immune-related adverse events (irAEs) in patients treated …
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON …
ML Johnson, BC Cho, A Luft… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy
C Liu, X Liu, X **ang, X Pang, S Chen, Y Zhang… - Nature …, 2022 - nature.com
The strategy of combining a vaccine with immune checkpoint inhibitors has been widely
investigated in cancer management, but the complete response rate for this strategy is still …
investigated in cancer management, but the complete response rate for this strategy is still …